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HSA carbonylation with methylglyoxal and the
binding/release of copper(II) ions
Ana Z. Penezic´, Vesna B. Jovanovic´, Ivan D. Pavic´evic´, Jelena M. Ac´imovic´ and
Ljuba M. Mandic´*†
The potential of carbonylation with methylglyoxal to alter HSA’s binding affinity for copper(II) ions and its
influence on the release of copper(II) ions from copper–HSA complexes were studied. The affinity of
HSA to coordinate copper(II) decreased upon carbonylation of the Cys34-SH group. Carbonylation of
copper–HSA complexes caused a decrease in Cys34-SH content, conformational changes and the
release of copper(II) ions. The ratio between the percentage of reduction in the Cys34-SH group content
and the percentage of release of copper(II) from complexes is 2.12  0.28. Because the same ratio
(1.96  0.36) was obtained upon oxidation of the Cys34-SH group (with no changes in HSA conformation),
the binding/release of copper (II) by HSA depended mainly on the redox state of the Cys34-SH group. The
contents of Cys34-SH and HSA-bound copper(II) ions in the diabetic group (0.457  0.081 mol SH per mol
HSA, 10.7  0.01 mmol per mol HSA, resp.) were significantly lower ( p o 0.01) compared to the control
group (0.609  0.027 mol SH per mol HSA; 13.4  0.01 mmol per mol HSA, resp.). Very strong
correlations between the values for HSA-SH and glycated haemoglobin, HbA1c, (R = 0.803, p o 0.01),
and between the values for the HSA-bound copper(II) content and HSA-SH content (R = 0.841, p o 0.002)
were found in the diabetic group. Thus, HSA carbonylation leads to decrease in HSA-SH content and to the
impairment of its copper(II) binding capacity that could contribute to further enhancement of oxidative and
carbonyl stress in diabetes (as well as in other diseases with carbonyl stress).
1 Introduction
Human serum albumin (HSA) is the most abundant serum
protein, with several important physiological functions.1,2 Besides
regulation of oncotic pressure, it also serves as a transporter of
metal ions (Cu, Zn, Fe, Co, Ni etc.), fatty acids, cholesterol,
hormones, drugs and bile pigments. HSA contains two binding
sites for copper ions, one with high affinity, located at the
N-terminus (NT, with 1 pM affinity), and second positioned at
the interface of domains I and II (multi-metal binding site,
MBS).3,4 Although ceruloplasmin represents a major pool of
copper in plasma, HSA, due to its high concentration, is
considered to be its second largest pool. About 15% of all blood
copper is bound to HSA as Cu(II).4 Copper(II) ion levels are
reported to be increased in diabetes and some other patho-
logical states,5,6 and any unbound copper(II) ions in circulation
may undergo Fenton reaction causing oxidative stress by the
formation of free radicals.7
Oxidative and/or carbonyl stress are believed to play an
important role in pathogenesis of various diseases e.g. uraemia,8
renal failure, diabetes mellitus9,10 etc. as well as in genesis of
secondary complications in diabetic patients involving micro-
angiopathies and cardio-vascular complications.11
HSA has 35 Cys residues, 34 of them being involved in 17
intramolecular disulfide bridges, and one, Cys-34, that is redox
active. With normal serum concentration between 35 and 50 g L1,
and 70–80% of its Cys34 in the reduced/sulfhydryl form, HSA
represents the predominant serum protein and a major plasma
antioxidant.1,2,12 Antioxidant properties of HSA depend on nucleo-
philic properties of Cys34 as well as on copper-binding ability.2,13
Both of these attributes may become impaired when HSA is
exposed to increased glycation, leading to protein modification,
formation of advanced glycated end-products (AGEs) and protein
cross-linking.14–18
Diabetes mellitus is one of the most prevalent chronic
diseases, affecting around 360 million people worldwide,19 of
which B90–95% are categorized as type 2.20 Hyperglycemia in
diabetes provokes Maillard reaction, formation of Schiff bases,
and Amadori products, and finally leads to generation of AGEs.21
Methylglyoxal (MG) represents a naturally occurring a-oxo-
aldehyde, generated either non-enzymatic, or from the sponta-
neous decomposition of triose phosphates, by autoxidation
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of carbohydrates, and glucose degradation, or by several minor
metabolic pathways including the Maillard reaction and lipid
peroxidation. The formation rate of MG in normal systems is
120 mmol per day, but several studies have shown that this rate in
diabetes is increased by 5- to 6-fold.22,23 Because of its high reacti-
vity (20000-fold more reactive than glucose24), MG represents a
potent modifying agent of proteins14,18 and nucleic acids.25
Thus, studies related to diabetic pathology reveal the existence
of oxidative stress in these patients, decreased content of the Cys34
thiol group,26 elevated levels of serum MG and copper(II) ions,
especially in type 2 diabetics.27,28 Recent studies regarding MG as
modifying agent of HSA (in vitro and in diabetes), and the ability of
glycated HSA to bind of copper(II) ions reported different opposite
results.29,30 Besides decrease in HSA-SH group content, carbonyl-
ation with MG leads to conformational changes in HSA
molecules,31 which could also influence HSA copper binding.
Therefore, the goal of this study was to determine the potential
of MG, as a modifying agent, to alternate HSA’s binding affinity
for copper(II) ions, i.e. the potential of reaction of carbonylation to
release copper(II) ions from copper–HSA complexes. The changes
in the Cys34 thiol group content and in the content of copper(II)
ions bound to HSA, and their ratios, as well as the changes in
conformation of HSA and copper–HSA complexes during carbonyl-
ation in vitro (with MG) and in diabetes type 2, were monitored.
Deciphering the effect of HSAmodification withMG on its ability to
bind and sequester copper(II) ions in circulation could prove useful
in treating secondary complications in diabetic patients.
2 Experimental
2.1. Chemicals and instrumentation
All chemicals were purchased from Merck (Darmstadt, Germany)
and Sigma-Aldrich Chemie (Steinheim, Germany) unless other-
wise noted. The 20% solution of HSA (96% purity, containing
0.40 mol SH per mol HSA) was purchased from Baxter (Vienna,
Austria).
Spectrophotometric measurements were performed using
a Beckman DU-50 spectrophotometer (Fullerton, CA, USA).
Fluorescence spectra were obtained on a Fluoromax-4 Jobin
Yvon (Horiba Scientific, Japan) spectrofluorimeter.
2.2. Serum samples
Blood samples were collected from patients with type 2 diabetes
who were hospitalized due to poor metabolic control (HbA1c
410.0%) and healthy volunteers of appropriate age and sex.
Informed consent was sought from all participants. Blood was
allowed to clot at room temperature, and serum was separated
by centrifugation (4000g, 10 min) and used immediately for HSA
isolation.
2.3. Isolation of HSA
HSA was isolated from serum by ammonium sulphate (AS)
precipitation using a two-step protocol following the method
of Jovanovic et al.32 Briefly, a stock solution of saturated AS
(pH 7.4) was added to the serum sample until a concentration
of 54% AS was reached. The precipitated proteins were removed
by centrifugation at 5000g for 10 min and the supernatant
containing HSA was collected. In the second step, a stock
solution of saturated AS (pH 7.4) was added to the supernatant
up to a final concentration of 70% AS. The precipitated HSA
was separated by centrifugation at 5000g for 10 min, and the
HSA pellet was resuspended in 0.1 M sodium phosphate buffer
(pH 7.4). To eliminate AS, HSA solution was further diluted by
the same buffer and concentrated by ultra-filtration (Ultracel-
10K, Millipore). The obtained HSA solution was used for further
analyses.
2.4. Thiol quantification
Serum total free thiol groups (protein and nonprotein, i.e., total
thiol content) and HSA-SH content were determined spectro-
photometrically according to a modified Ellman’s method.33
DTNB reagent (5,50-dithiobis-(2-nitrobenzoic acid), 100 mL of
2 mM solution) was mixed with equal volumes of sample and
1 M Tris buffer (pH 8.0) and brought up to 1000 mL with water.
Absorbance was measured after 30 min at room temperature at
412 nm against the sample and reagent blanks. The concentration
of thiols was calculated by using the molar extinction coefficient
(13 600 mol L1 cm1). Values were expressed in mol L1 for
serum and mol SH per mol HSA.
2.5. HSA–copper(II) content
This was quantified by using bathocuproinedisulfonic acid
disodium salt (BCDS) as the chelator. The BCDS–Cu(I) complex
exhibits a maximum of absorbance at 480 nm. Absorbance was
recorded after mixing the samples with ascorbate (800 mM); in
order to reduce Cu(II) to Cu(I) and BCDS (400 mM) against the
sample and reagent blanks. Measurements were performed
in triplicate and at room temperature. The concentration of
copper(II) ions was calculated using a calibration curve prepared
for CuSO4 in PBS (5–200 mM, R = 0.9997, P o 0.0001). Values
were expressed in mol per mol HSA.
2.6. Preparation of highly reduced HSA (mercapto-HSA)
Commercial HSA contains 0.4 mol SH group per mol HSA,
so for experiments in which the HSA-SH content needed to be
higher than 0.4 mol-SH per mol HSA, commercial HSA was
reduced with dithiothreitol. Prior to the reduction, the content
of the HSA-SH group was determined. An appropriate amount
of HSA was mixed with dithiothreitol at a molar ratio of 1 : 1
(molar content of oxidized thiol group : dithiothreitol) for 1 h at
37 1C in 0.1 M sodium phosphate buffer, pH 7.4. Subsequently,
dithiothreitol was washed away from HSA with 0.1 M sodium
phosphate, pH 7.4, using an Ultracel-30K device (Millipore, USA).
After this treatment, the HSA-SH content was 0.89 mol SH group
per mol HSA.
2.7. Preparation of in vitro carbonylated HSA
Carbonylated HSA was prepared by incubating 0.5 mM HSA
with MG (10 mM) at 37 1C for 24 h in PBS (pH = 7.4). Following
incubation, samples were washed with PBS from any unreacted
MG using an Ultracel-30K Millipore ultrafiltration device.
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2.8. Preparation of HSA–Cu(II) complexes
An aliquot of CuSO4 solution in 10 mM PBS (pH = 7.4) was
added to HSA samples (0.5 mM) in order to obtain HSA–Cu(II)
complexes (0.05, 0.1 and 0.2 mol of copper(II) per mol HSA for
Complexes I, II and III resp.). The mixture was incubated for
40 min at 4 1C in the dark (according to Gryzunov et al.34). Any
unbound copper(II) ions were removed by washing the samples
five times with PBS (1 : 15, vol/vol; 10 mM, pH = 7.4) using an
Ultracel-30K device (Millipore, USA).
2.9. HSA assay
HSA concentration was measured by a Biuret reaction,35 using a
HSA standard curve (concentration range from 1 to 100 g L1,
R = 0.999).
2.10. Fluorescence spectroscopy
The protein concentration used for fluorescence measurements
was 2 mM. The spectra were recorded in the wavelength range of
300 to 450 nm following excitation at 295 nm using a quartz cell
(1 cm path length) and slit widths (4 nm). Each spectrum was
the average of two scans and the respective blanks of PBS were
used for the correction of all fluorescence spectra.
2.11. Native PAGE
Native-PAGE (polyacrylamide gel electrophoresis) was performed
according to the manufacturer’s recommendations using a Hoeffer
SE 260 electrophoretic unit (San Francisco, CA, USA), and densito-
metric analyses of gel by using ImageJ software.
2.12. Statistical analysis
Data are expressed as mean values standard deviation from at
least three different experiments. Statistical significances were
determined by using Student’s t-test (P values less than 0.05
were considered statistically significant), and statistical correla-
tion by determining Pearson’s correlation coefficient.
3 Results and discussion
3.1. The copper(II) binding affinity of carbonylated HSA
HSA is a metal ion transporter having one high-affinity binding
site for copper(II) ions located on the N-terminus. Contradictory
results have been observed for copper(II) binding capacity in the
amino terminus binding site of glycated HSA.2 Having in mind
that unbound copper(II) ions can undergo Fenton/Haaber Weiss
reaction leading to free radical production, a decrease in HSA
copper binding affinity/capacity would contribute to the develop-
ment of oxidative stress. Therefore, it is of interest to investigate
the copper binding affinity of carbonylated HSA.
In order to investigate the influence of HSA carbonylation
on copper(II) binding affinity, mercapto-HSA (with 0.879 mol
SH per mol HSA) was pre-incubated with 10 mMMG for 24 h at
37 8C. The obtained carbonylated HSA (HSA-MG; with the thiol
group content of 0.587 mol SH per mol HSA), as well as each
mercapto and commercial HSA (0.400 mol SH per mol HSA)
were incubated with three different concentrations of copper(II)
ions (0.05, 0.10 and 0.20 mol of copper(II) per mol HSA). These
Cu(II) concentrations were used because we wanted to have one
(nearly) physiological, one slightly elevated and one supra-
physiological saturation in order to be able to relate to physio-
logical and pathological conditions during carbonylation with MG,
and see if there is a significant difference in Cu(II) binding capacity
of HSA. The content of bound copper in thus formed copper–HSA
complexes I, II and III (resp.) was determined (Table 1). The
mercapto-HSA sample (with 0.879 mol SH per mol HSA) is able to
bind all available copper(II) ions. On the other hand, commercial
HSA with 0.400mol SH permol HSA binds 14.4%, 15.6% and 29.9%
less copper(II) ions than mercapto-HSA. These results suggested that
the copper binding capacity of HSA is positively correlated with HSA-
SH content, which is in accordance with the results of Zhang and
Wilcox36 who found that both in vitro and in vivo Cu(II) ions
preferently bind to albumin with reduced Cys34. The redox state
of Cys34 was found to affect the chemical environment of His3,
located B20 A away37 included in copper coordination besides
the N-terminal amine and the first two deprotonated amides.
In comparison to mercapto-HSA, carbonylated HSA samples
(with 0.587 mol SH per mol HSA) bind copper(II) ions with
reduced capacity (15.2%, 15.5% and 18.2% resp.) (Table 1).
This capacity reduction could be the consequence of decrease
in the thiol group content, and also of the conformational changes
in HSA (as Lys and Arg residues are also targeted during protein
modification with MG).15 The changes in the three-dimensional
structure were confirmed by recording the fluorescence emission
spectra (Fig. 1).
Due to carbonylation of the HSA molecule, the quenching of
internal fluorescence (originating from Trp214 after excitation
Table 1 The influence of HSA-SH content on copper(II) binding affinity of mercapto-HSA (0.879 mol SH per mol HSA), commercial HSA (0.400 mol SH
per mol HSA) and HSA-MG (0.587 mol SH per mol HSA). Copper–HSA complexes I, II and III are obtained during incubation with 0.05, 0.10 and 0.20 mol
of copper(II) per mol HSA, resp. Each experiment was done in triplicate
Copper–HSA complex
The content of Cu(II) ions bound to
Decrease in the content of Cu(II)
ions bound to HSA (%)
Mercapto-HSA
(mol per mol HSA  SD)
Commercial HSA
(mol per mol HSA  SD)
HSA-MG
(mol per mol HSA  SD)
Commercial HSA vs.
mercapto-HSA
HSA-MGa vs.
mercapto-HSA
I 0.0512  0.0035 0.0438  0.0034 0.0434  0.0013 14.4 15.2
II 0.0959  0.0038 0.0809  0.0021 0.0810  0.0021 15.6 15.5
III 0.2025  0.0042 0.1420  0.0064 0.1655  0.0019 29.9 18.2
a HSA-MG, HSA carbonylated with methylglyoxal.
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of HSAmolecule at 295 nm) at lem = 346 nm by 46% compared to
the unmodified HSA was observed. The differences in fluores-
cence intensity of HSA and HSA-MG do not arise from changes in
their secondary structure (far-UV CD spectra are not shown).
These results confirmed alterations in the capacity of HSA
with low HSA-SH content to bind to copper(II) ions. The reaction
of carbonylation leads to decrease in HSA copper(II) binding
affinity, having important implications considering the involve-
ment of free copper ions in the development of oxidative stress
in diabetes (and other diseases with carbonyl stress).
3.2. Does carbonylation of the Cys34 thiol group influence the
release of copper(II) from copper–HSA complexes?
To answer this question, mercapto-HSA (with 0.879 mol SH per
mol HSA) was first pre-incubated with three concentrations of
copper(II) ions (0.05, 0.10 and 0.20 mol of copper(II) per mol
HSA). The obtained copper–HSA complexes (I, II and III), as well
as mercapto-HSA were subsequently incubated (carbonylated)
with 10 mMMG for 24 h at 37 1C (copper–HSA I-MG, copper–HSA
II-MG, copper–HSA III-MG and mercapto-HSA-MG). The content
of HSA-SH groups and the content of HSA bound copper(II) ions in
all the samples were determined (Table 2).
The incubation of mercapto-HSA for 24 h at 37 1C, leads to
decrease in HSA-SH content for almost 9%, caused by aerobic
oxidation of the Cys34 free thiol group. The decrease in the
thiol group content obtained for copper–HSA complexes I, II and
III was different (6.9%, 10.3% and 15.1% resp.).
These changes implied the existence of the correlation between
the thiol group content and the amount of bound copper ions. In
order to perceive if this decrease is caused by binding of copper(II)
ions (during preparation of complexes I, II and III) or, is the
consequence of aerobic oxidation, or both, the content of HSA-
SH groups of copper–HSA complexes obtained by incubation of
mercapto-HSA with five copper concentrations (0.05, 0.08, 0.10,
0.16 and 0.20 mol Cu(II) per mol HSA) during 40 min, was tested
(Table 3).
These data showed that loading HSA with copper(II) ions
leads to decrease in Cys34 free thiol group content, and that
this decrease is proportional to the concentration of copper(II)
ions (a Pearson’s correlation coefficient R = 0.996, Fig. 2A).
Comparison of thiol group changes obtained after 40 min
(complex time preparation, Table 3) and 24 h (incubation time,
Table 2) showed no significant differences (5.8%, 8.8% and
13.7% vs. 6.9%, 10.3% and 15.1%). Thus, it could be concluded
that binding of copper(II) ions to HSA leads to decrease in the
Cys-thiol group content. These results suggest that copper(II)
ions, during the course of forming complexes with HSA mole-
cules, could cause the oxidation of Cys34 (and thus affect the
redox state of HSA34). Densitometric analyses of gel obtained by
native-PAGE of mercapto-HSA and copper–HSA complex II (Fig. 2B)
showed an increase of 10% in the intensity of the dimer band in
copper–HSA complex II, compared to the dimer band present
in mercapto-HSA. This percent corresponds to the percent of
decrease in the thiol group content obtained after 24 h of
incubation (10.3%), suggesting that copper(II) ions cause oxida-
tion of free Cys34-thiol groups into a disulfide bridge formed
between two HSA molecules.
The carbonylation of mercapto-HSA (HSA-SH content
0.879 mol per mol HSA, control) with MG for 24 h caused a
decrease in HSA-SH content of 33.2% (Table 2), which is in
accordance with the previously published data.15 A similar
decrease in the content of HSA-SH groups was obtained for
copper–HSA complexes (I-MG, II-MG and III-MG: 31.7%, 33.3%
and 38.8%, resp.). However, when the decrease in HSA-SH con-
tent caused by the preparation of the copper–HSA complexes
Fig. 1 (A) Fluorescence emission spectra of mercapto-HSA (HSA) and HSA
carbonylated with MG (HSA-MG), copper–HSA complex II (copper–HSA)
and copper–HSA complex II modified with MG (copper–HSA-MG), HSA
isolated from the serum of healthy (control) and diabetic persons (diabetic).
Excitation at 295 nmwas used, and emission was recorded in the range from
300 to 450 nm. (B) The reduction of fluorescence intensity of HSA samples in
comparison to mercapto-HSA, at the peak wavelength.
Table 2 The influence of carbonylation of mercapto-HSA (with 0.879 mol SH per mol HSA) and HSA–copper complexes (I, II and III) with methylglyoxal
on the contents of the Cys34-SH group and the HSA bound Cu(II) ion. Each experiment was done in triplicate and results are presented as mean
value  SD
Sample
HSA-SH content following
24 h incubation
(mol SH per mol HSA)
Decrease in HSA-SH
content compared to
mercapto-HSA (%)
Content of HSA bound Cu(II)
ion (mol per mol HSA)
Decrease in Cu(II)
ion content (%)0 h 24 h
Mercapto-HSA 0.800  0.046 8.9 — — —
Copper–HSA I 0.818  0.030 6.9 0.0511  0.0035 0.0496  0.0035 2.9
Copper–HSA II 0.788  0.030 10.3 0.0979  0.0038 0.0920  0.0015 6.0
Copper–HSA III 0.746  0.028 15.1 0.2025  0.0042 0.1855  0.0032 8.4
Mercapto-HSA-MG 0.587  0.049 33.2 — — —
Copper–HSA I-MG 0.600  0.021 31.7 0.0511  0.0035 0.0432  0.0042 15.5
Copper–HSA II-MG 0.586  0.041 33.3 0.0979  0.0038 0.0814  0.0033 16.8
Copper–HSA III-MG 0.538  0.060 38.8 0.2025  0.0042 0.1675  0.0019 17.3
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(I, II and III), is taken into account, it can be noticed that the
percentage of HSA-SH groups which react with MG is lower
(24.8%, 23% and 23.6%, resp.). The decrease in the Cys34-thiol
group content resulted in the reduction of HSA-bound copper(II)
ion content of 15.5%, 16.8% and 17.3% resp. (Table 2). Thus,
copper(II) ions are released from HSA molecules during their
carbonylation with MG. In order to test if carbonylation of the
Cys34 free thiol group is the underlying cause for the release of
copper(II) ions from copper–HSA complexes during incubation
with MG, the HSA-bound copper(II) and the Cys34-SH group
contents were measured in aliquots taken from the incubation
mixture (Fig. 3A). The time course curve of Cys34-SH group
carbonylation is similar to the copper releasing curve. The release
of copper(II) ions occurred in the first three to four hours of the
incubation of HSA–copper(II) complex with MG. The ratios
between the percentage of reductions (Cys34-SH group content/
HSA bound copper) upon HSA carbonylation were in the range
from 0.21 to 2.1 (Fig. 3B).
These results show that similar to copper binding, the release
of copper(II) from copper–HSA complexes during carbonylation is
strongly dependant on the redox state of the Cys34-thiol group. In
addition, it should be underlined that the percentage of decrease
in HSA bound copper content, obtained during copper binding
capacity investigations of carbonylated HSA-MG (15.2%, 15.5%
and 18.2% resp., Table 1) and the percentage of copper release
from copper–HSA-MG complexes during carbonylation (15.5%,
16.8% and 17.3% resp.) are almost equal. This result would be
expected if decrease in thiol group content was considered to be
the only cause of observed HSA binding capacity changes, as in
both experiments the same concentration of MG was used.
Nevertheless, since Cu(II) ion forms strong tetragonal complexes
with biological nitrogen ligands (which is important for fast
exchange of ligands in terms of intracellular transfers of this
metal38) the observed release of copper(II) ions bound to HSA
could also be the consequence of HSA conformational changes
due to carbonylation. The conformational changes in HSA-MG
and copper–HSA-MG obtained by florescence spectroscopy, i.e.
quenching of internal fluorescence at lem 346 by 46.3% and
44.1% (resp.) are nearly identical in comparison to unmodified
Table 3 The changes in thiol group content during the preparation of
copper–HSA complexes. The incubation of mercapto-HSA (0.879 mol SH
per mol HSA) with five different concentrations of copper ions was done in the
dark, during 40 min at +4 1C (pH 7.4). Each experiment was done in triplicate
Content of Cu(II)
ions incubated with
mercapto-HSA
(mol per mol HSA)
Content of HSA-SH
groups after incubation
of mercapto-HSA
with Cu(II) ions
(mol per mol HSA)
Decrease in the
HSA-SH group content
(mol SH per
mol HSA) (%)
0.05 0.828  0.003 0.051  0.003 5.8
0.08 0.806  0.005 0.073  0.006 8.3
0.10 0.802  0.010 0.077  0.011 8.8
0.16 0.779  0.004 0.100  0.003 11.4
0.20 0.759  0.008 0.120  0.008 13.7
Fig. 2 (A) Correlation between the HSA-SH content and the content of
copper(II) ions bound to mercapto-HSA. (B) Native-PAGE of copper–HSA
complex II (lane 1) and mercapto-HSA (lane 2). The electrophoresis was
performed on 10% polyacrylamide gel. 2 mg of protein was applied per
lane. Arrow indicates the HSA dimer band.
Fig. 3 (A) The time course curves of reduction in the contents of HSA-bound copper(II) ions and HSA-SH groups during incubation of copper–HSA
complex II with 10 mM methylglyoxal (37 1C, pH = 7.4). (B) The ratios of reduction in the Cys34-SH group content and HSA bound copper content upon
HSA carbonylation.
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mercapto-HSA (Fig. 1). The ratio between the percentage of
reduction in the Cys34 thiol group content due to carbonylation
of copper–HSA complexes and the percentage of release of
copper from complexes is 2.12  0.28 (Table 4). The value of this
ratio, obtained when oxidation of the thiol group (1.96  0.36)
occurs, is almost equal to the value obtained after carbonylation
of the thiol group with MG. Because the HSA conformation and
Cys34-SH accessibility39 are changed during carbonylation, but
not after HSA-SH oxidation (Fig. 1), these results indicate that the
binding/release of copper (II) ions by HSA depends mainly on the
redox state of the free thiol group. Thus, if the Cys34 residue
becomes carbonylated with MG, the copper(II) binding capacity of
HSA reduces, and copper(II) ions are released from the complex
copper–HSA-MG. The increase in flux of MG and the other
reactive dicarbonyl compounds (glyoxal and 3-deoxyglucosone)
occurring during carbonyl stress (in diabetes, Alzheimer’s
disease, renal failure, liver cirrhosis, anemia, uremia, and
atherosclerosis)40 could lead to the Cys34 side chain carbonyl-
ation and therefore to the decrease in HSA-SH and HSA-bound
copper contents. This, also, implicates the question of the corre-
lation between these two parameters under real physiological
conditions.
3.3. Changes in the HSA-SH group and HSA-bound copper(II)
content in diabetic patients
To perceive the above given conclusion, sera andHSA of 11 patients
with diabetes type 2 and 10 healthy persons were analyzed in order
to determine the contents of total serum thiols, total serum
copper(II), HSA-SH groups, and HSA-bound copper(II) (Table 5).
HbA1c content in the diabetic group was significantly higher
( p o 0.05) compared to the control group. In the HSA sample
isolated from the serum of diabetic persons (diabetic), the
quenching of internal fluorescence at lem = 346 nm (originating
from Trp214 after excitation of the HSA molecule at 295 nm) by
23%, compared to the HSA of healthy person (control), was
observed (Fig. 1). Thus, HSA glycation in hyperglycemia leads to
change in HSA conformation. In addition, AGEs show fluorescence
after excitation at lexc higher than 290 nm, i.e. they have char-
acteristic excitation at wavelengths in the range of 328 to 370 nm
and fluorescence emission from 378 to 440 nm. The monitoring of
the fluorescence at leksc/lem = 365/440
41 or 370/43042 was sug-
gested as an indicator of the protein glycation level. Fluorescence
emission spectra of HSA samples isolated from the serum of
healthy (control) and diabetic persons (Fig. 4), recorded in the
wavelength range of 380 to 500 nm following excitation at 365 nm,
are the approval that HSA modification occurred.
The total serum copper(II) ion content in diabetic patients was
higher than in the control group, which is in accordance with the
results of several studies.43,44 In contrast, the total serum thiol
content was lower. The HSA-SH group content in the diabetic
group is 24.9% lower compared to the control group, which is in
accordance with the results from in vitro experiments and with
our previously reported HSA-thiol group content decrease in
diabetes.32 This difference is statistically significant ( p o 0.01).
As it was expected, based on in vitro experiments, the content of
HSA-bound copper(II) ions in the diabetic group was also signifi-
cantly lower ( p o 0.01) in comparison to the control group.
Decreased levels of HSA-bound copper(II) ions in diabetes were
also found by Guerin-Dubourg et al.30 When the ratio between
the percentages of decrease in the Cys34-SH group content and
HSA bound copper content in the diabetic group were compared
to the control, the values from 0.51 to 2.54 were obtained (almost
identical to the above given in vitro results).
There is a negative correlation between the values for HSA-
SH content and the HbA1c fraction, as well as for total serum
thiol content and HbA1c fraction (R = 0.803, p o 0.01; R =
0.716, p o 0.05 resp.) in the diabetic group. In contrast, very
good positive correlation (R = 0.841, p o 0.002) between the
HSA-SH group contents and values of HSA-bound copper(II)
ions was found in the diabetic group. These results confirm our
hypothesis that modification of the HSA molecule in patients
with diabetes type 2 causes a decrease in the Cys34 thiol group
content, leading to the impairment of its copper(II) binding
capacity. The increase of the free copper(II) ions in serum could
Table 4 Dependence of copper(II) ion release from copper–HSA complexes
during oxidation and carbonylation of the Cys34 thiol group
Thiol group
Decrease in
HSA-SH
content (%)
Decrease in
the Cu(II)
ion content (%) Ratio
Ratio mean
value
Oxidation 6.9 2.9 2.38 1.96  0.36
10.3 6.0 1.71
15.1 8.4 1.80
Carbonylation 24.8 12.9 1.92 2.12  0.28
23.0 11.5 2.00
23.6 9.7 2.44
Table 5 HbA1c fraction and the contents of thiol groups and copper(II)
ions in serum and HSA, in diabetes type 2 patients and healthy individuals
Diabetic patients Control
n 11 10
HbA1c (%) 10.25  1.52* 5.59  0.53
Total serum Cu2+ (mM) 34.3  8.1 28.5  1.7
Total serum-SH (mM) 0.330  0.059** 0.427  0.037
HSA-SH (mol SH per mol HSA) 0.457  0.081** 0.609  0.027
Copper–HSA (mmol per mol HSA) 10.7  0.01** 13.4  0.01
*po 0.05, compared to control group; **po 0.01, compared to control
group.
Fig. 4 Fluorescence emission spectra of HSA isolated from the serum of
healthy (control) and diabetic persons (diabetic). Excitation at 365 nm was
used, and emission was recorded in the range from 360 to 500 nm.
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contribute to the increase of reactive oxygen species.2 Free
copper(II) can react with hydrogen peroxide (via the Fenton reac-
tion) leading to the formation of hydroxyl radicals 60 times faster
than iron.2 Free copper(II) ions increase glucose autoxidation,
causing formation of the shorter-chain reactive carbonyl com-
pounds,45 and acceleration of alpha-oxoaldehyde formation
from early glycation products.46 On the other hand, as the HSA-
SH group constitutes an important redox regulator in extracellular
compartments,47 its decrease due to carbonylation leads also to
the decrease of HSA antioxidative potential.48 Thus, carbonylation
of HSA-SH leads to consequences that cause further enhancement
of oxidative and carbonyl stress.
4 Conclusions
Overall, the reaction of HSA carbonylation in vitro (with MG) and
in vivo (diabetes in which increasing flux of carbonyl species
occurs) leads to decrease of its copper(II) binding affinity, i.e. to
the release of copper(II) ions from copper–HSA complexes in an
extent which depends mainly on the redox state of the Cys34 free
thiol group. The decrease of the HSA-SH content and increase
of the free copper ions in serum could contribute to further
enhancement of oxidative and carbonyl stress.
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